Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 13/20 | 0.51 |
| ▸ | GIPR | P48546 | 12/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATP4A | P20648 | 2/20 | 0.45 |
| ▸ | ATP4B | P51164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100396 | 0.90 | GCGR (0.49) | GCGRGIPRSIRT5TP53MAPT | |
| SCHEMBL1746924 | 0.87 | KMT2A (0.52) | TP53MAPTALDH1A1L3MBTL1GSTO1 | |
| SCHEMBL1099079 | 0.85 | ATP4A (0.48) | GCGRGIPRATP4AATP4BALDH1A1 | |
| SCHEMBL2647516 | 0.81 | GCGR (0.73) | GCGRGIPR | |
| SCHEMBL7221406 | 0.80 | MAPT (0.59) | SIRT5TP53MAPTATP4AATP4B | |
| SCHEMBL1745385 | 0.79 | PPARD (0.55) | GCGRGIPRATP4AATP4B | |
| SCHEMBL1744789 | 0.79 | KMT2A (0.54) | TP53MAPTALDH1A1L3MBTL1GSTO1 | |
| SCHEMBL3451487 | 0.79 | KMT2A (0.54) | TP53MAPTALDH1A1L3MBTL1GSTO1 | |
| SCHEMBL1198879 | 0.78 | ALDH1A1 (0.56) | GCGRGIPRSIRT5TP53MAPT | |
| SCHEMBL28715169 | 0.78 | ALDH1A1 (0.56) | GCGRGIPRSIRT5TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1916234-B1 | CYCLOPROPANECARBOXYLIC ACID COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-1916234-B1 | CYCLOPROPANECARBOXYLIC ACID COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8153694-B2 | Cyclopropanecarboxylic acid compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153694-B2 | Cyclopropanecarboxylic acid compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153694-B2 | Cyclopropanecarboxylic acid compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100144806-A1 | Cyclopropanecarboxylic Acid Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144806-A1 | Cyclopropanecarboxylic Acid Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144806-A1 | Cyclopropanecarboxylic Acid Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| EP-1916234-A1 | CYCLOPROPANECARBOXYLIC ACID COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-1916234-A1 | CYCLOPROPANECARBOXYLIC ACID COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144806-A1 | Cyclopropanecarboxylic Acid Compound | GPR65, GPR34, GPR68 | GCGR 89/4885GIPR 98/4885SIRT5 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.